Table 4

Treatment characteristics

No. of cyclesPatients
n = 44 (%)
15 (11)
212 (27)
32 (5)
425 (57)
Dose modifications
No. of patients (%)No. of cycles (%)
IL-2/IFNa
50% reduced14 (32)21 (16)
Discontinued5 (11)5 (4)
DTIC/VBLb,c
25% reduced13 (30)18 (14)
50% reduced6 (14)6 (5)
CDDPd
25% reduced5 (11)10 (8)
50% reduced0 (0)0 (0)
  • a IL-2/IFN: modified for hypotension, neurotoxicity (1), or cardiac (1).

  • b VBL, vinblastine.

  • c DTIC/VBL: modified for hematological toxicity.

  • d CDDP: modified for nausea/vomiting.